ijms-logo

Journal Browser

Journal Browser

Translating Molecular Psychiatry: From Biomarkers to Personalized Therapies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 1715

Special Issue Editor


E-Mail
Guest Editor
Danube Neuroscience Research Laboratory, HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), Tisza Lajos krt. 113, H-6725 Szeged, Hungary
Interests: depression; anxiety; dementia pain; their comorbidities nature; translational research in neurological diseases and psychiatric disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We invite submissions for a Special Issue dedicated to the transformative potential of translational research in molecular psychiatry. This issue seeks to bridge the gap between cutting-edge molecular insights and their practical application in clinical settings, focusing on key areas that promise to revolutionize psychiatric care. We welcome contributions that investigate the identification and validation of molecular biomarkers, such as genetic markers and metabolites, which are critical for improving diagnostic precision and tailoring personalized treatment plans in psychiatric disorders. These advancements are fundamental to the development of precision medicine in mental health.

The Special Issue also welcomes papers on pharmacogenomics, emphasizing how genetic variations influence individual responses to psychiatric medications. Research in this area can significantly reduce adverse effects and optimize therapeutic outcomes by guiding personalized drug regimens. Furthermore, we are looking for studies on gene-environment interactions in psychiatric disorders that will help us understand the complex interplay between genetic predispositions and environmental triggers, with the goal of informing the design of targeted prevention and intervention strategies.

Further, we highlight the importance of neuroinflammation and immune modulation in understanding and treating psychiatric conditions, alongside the role of neuroimaging and molecular imaging in correlating molecular changes with clinical symptoms. This issue aims to advance the field by accelerating the translation of molecular research into effective clinical innovations, ultimately improving patient care and outcomes in psychiatry.

Dr. Masaru Tanaka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular psychiatry
  • biomarkers
  • pharmacogenomics
  • precision medicine
  • gene-environment Interaction
  • neuroinflammation
  • immune modulation
  • neuroimaging
  • molecular imaging
  • psychiatric disorders

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

9 pages, 1222 KiB  
Brief Report
IL-1 Blockade Mitigates Autism and Cerebral Palsy Traits in Offspring In-Utero Exposed to Group B Streptococcus Chorioamnionitis
by Taghreed A. Ayash, Marie-Julie Allard, Mathilde Chevin and Guillaume Sébire
Int. J. Mol. Sci. 2024, 25(21), 11393; https://doi.org/10.3390/ijms252111393 - 23 Oct 2024
Viewed by 1196
Abstract
Group B Streptococcus (GBS) is one of the most common bacteria responsible for placental and neonatal infection and inflammation resulting in lifelong neurobehavioral impairments. In particular, GBS-induced chorioamnionitis is known in preclinical models to upregulate inflammatory pathways, primarily through the activation of the [...] Read more.
Group B Streptococcus (GBS) is one of the most common bacteria responsible for placental and neonatal infection and inflammation resulting in lifelong neurobehavioral impairments. In particular, GBS-induced chorioamnionitis is known in preclinical models to upregulate inflammatory pathways, primarily through the activation of the interleukin-1 (IL-1) pathway, leading to brain injury and subsequent neurodevelopmental issues. Previous studies from our laboratory using Lewis rat pups have shown that male offspring exposed in utero to GBS chorioamnionitis develop brain injuries leading to neurobehavioral impairments such as autistic traits. In the present study, we aimed to explore whether blocking the IL-1 pathway could prevent or mitigate these neurodevelopmental impairments in adulthood. Using our established preclinical model, we administered IL-1 receptor antagonist (IL-1Ra) to dams with GBS-induced chorioamnionitis. Here, we show that IL-1Ra administration to dams reversed autistic and cerebral palsy traits in male adult offspring exposed in utero to GBS. Hence, IL-1 blockade could serve as a therapeutic intervention against pathogen-induced neurodevelopmental disorders. This research supports the need for future human randomized controlled trials to assess IL-1 blockade administered during pregnancy or in newborns as a strategy to reduce the long-term neurobehavioral consequences of prenatal infections, such as autism, cerebral palsy, learning disabilities, and other neurodevelopmental disorders. Full article
Show Figures

Figure 1

Back to TopTop